Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results covered quarter ended June 30, 2026.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 fiscal 2026 results covered quarter ended June 30, 2026
- Business and clinical update accompanied financial results
- Detailed financial figures and outlook contained in Exhibit 99.1 press release
- Disclosure furnished under Regulation FD, limiting Section 18 liability for investors
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $19.9M, up from $15.7M, with product sales rising to $19.8M on stronger Elfabrio demand
- Six-month revenue $53.6M included a $25.0M Chiesi milestone, making recurring commercial revenue quality especially important
- Six-month net income $22.1M, or $0.28 basic EPS, versus a $3.5M loss in 2025
- Cash and short-term deposits $40.7M, with no outstanding debt or warrants, supporting PRX-115 Phase 2 execution
- 2026 revenue guidance reaffirmed at $78.0M-$83.0M, with PRX-115 top-line results expected in the second half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.